{"filing":{"accession_number":"0001630627-26-000017","cik":"0001630627","ticker":"TMCI","company_name":"TREACE MEDICAL CONCEPTS, INC.","form":"8-K","filing_date":"2026-08-07","report_date":"2026-08-07","primary_document":"tmci-20260807.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1630627/000163062726000017/tmci-20260807.htm"},"events":[{"id":26233,"run_id":23826,"accession_number":"0001630627-26-000017","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Treace Medical's Q2 2026 financial results. The filing explicitly states \"On August 7, 2026, Treace Medical Concepts, Inc. (the 'Company') issued a press release regarding its financial results for the quarter ended June 30, 2026\" under Item 2.02. The press release reports revenue of $45.4 million (down 4% YoY), net loss of $(15.9) million, and updated full-year 2026 guidance. This is material to investors as it provides quarterly operating performance and forward guidance.","company_name":"TREACE MEDICAL CONCEPTS, INC.","ticker":"TMCI","filing_date":"2026-08-07","form":"8-K","submitted_at":null,"items":[{"id":27274,"accession_number":"0001630627-26-000017","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Treace Medical's Q2 2026 financial results. The filing explicitly states \"On August 7, 2026, Treace Medical Concepts, Inc. (the 'Company') issued a press release regarding its financial results for the quarter ended June 30, 2026\" under Item 2.02. The press release reports revenue of $45.4 million (down 4% YoY), net loss of $(15.9) million, and updated full-year 2026 guidance. This is material to investors as it provides quarterly operating performance and forward guidance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T02:18:31.613640+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27274,"accession_number":"0001630627-26-000017","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Treace Medical's Q2 2026 financial results. The filing explicitly states \"On August 7, 2026, Treace Medical Concepts, Inc. (the 'Company') issued a press release regarding its financial results for the quarter ended June 30, 2026\" under Item 2.02. The press release reports revenue of $45.4 million (down 4% YoY), net loss of $(15.9) million, and updated full-year 2026 guidance. This is material to investors as it provides quarterly operating performance and forward guidance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T02:18:31.613640+00:00","company_name":"TREACE MEDICAL CONCEPTS, INC.","ticker":"TMCI","filing_date":"2026-08-07"}]}